Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Ensayos epigenéticos basados en reacción en cadena de la polimerasa para diagnóstico precoz del cáncer

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TORU20150219002
Publicado:
03/06/2015
Caducidad:
02/06/2016
Resumen:
Una empresa rusa ha desarrollado un método de reacción en cadena de la polimerasa basado en una nueva clase de enzimas de ADN sensibles a metilación para determinar la metilación funcional de las regiones reguladoras de genes. Partiendo de este método, la empresa está desarrollando ensayos epigenéticos para el diagnóstico precoz del cáncer. Este método ofrece una alta sensibilidad y una precisión de los resultados entre el 95 y 97%. Se buscan socios industriales e investigadores con el fin de establecer acuerdos de cooperación técnica e investigación.

Details

Tittle:
Epigenetic test systems based on polymerase chain reaction for early oncology diagnostics
Summary:
Russian company has developed a polymerase chain reaction method of determination of the functional methylation of genes regulatory regions based on a new class of methylation sensitive DNA enzymes. Based on this method the epigenetic test systems for realization of early oncology diagnostics are in development.
The company searches for partners for technical cooperation and/or for research cooperation agreement.
Description:
Efficiency of cancer treatment directly depends on early diagnostics. The innovative Russian company has discovered a new class of methylation sensitive DNA enzymes, based on this class there has been developed a polymerase chain reaction method of determination of the functional methylation of the genes regulatory regions defining the gene status: whether it is "switched on" or "switched off". The method has been already tested for patients with breast cancer (high indices of efficiency were reached). The method is a simpler, cheaper, clinically applicable alternative for the bisulfate conversion method for the oncologic diseases revealing. It is shown that the major part of oncologic diseases is caused by the functional methylation (switching off) of tumor suppressor genes. Based on this method, there are being developed epigenetic test systems for early oncodiagnostics, population screening. The development of any other epigenetic test systems based on main method is possible.
By the current moment, there are no analogues of a similar method and test systems with similar characteristics in the world market. Required partners are the industrial or/and research organizations. The company offers a technological know-how or an innovative product for the subsequent introduction of medical technologies procedures to the world market and/or searches for the partner for joint R&D work, possibly within the framework of a project for the research and technical program (ERANET.RUS, ERA-SME, M-ERA, bipartite programs between the Russian Federation and the countries of the European union).
Advantages and Innovations:
Novelty of this method and developed test systems is in using the new class of methylation sensitive DNA enzymes.
The major advantages of the given method over present procedures by today:
1). By using this method, it is possible to perform the earliest diagnostics since it all works at the level of organism controlling mechanisms.
2). The method itself and the test system do not require special equipment, and high personnel qualifications is also not required.
3). High sensitivity and diagnostics result precision (95 - 97 %), unlike presently existing in the market.
4). The test system requires just blood analysis.
5). High result repeatability.
Stage of Development:
Prototype available for demonstration
IPs:
Secret Know-how,Patent(s) applied for but not yet granted,Patents granted
CommeR Statunts Regarding IPR Status:
RF, 2009-2011

Partner sought

Type and Role of Partner Sought:
The industrial or research organization.
Organizations, solution developers in the sphere of new types of DNA cleaving enzymes
1). Joint development of the test systems based on polymerase chain reaction analysis method. The partner should have its own clinical site (for example, university hospital). The company's object is startup of the basic technology; the partner's object is its refinement in sick and healthy volunteers.
2). Joint participation together with the company in competitions of scientific and technical programs for development of any other epigenetic test systems.

Client

Type and Size of Client:
Industry >500
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English

Keywords

Technology Keywords:
06003003 Genética poblacional
06002005 Ingeniería genética
06001002 Investigaciones clínicas, ensayos
06001015 Productos farmacéuticos / medicamentos
06001009 Terapia genética - ADN